Furthermore, Dowling highlighted that metformin-mediated AMPK activation led to mechanistic target of rapamycin (mTOR) inhibition and a decrease in translation initiation, suggesting a potential mechanism of action for the drug in slowing down the proliferation of cancer cells in a preclinical study (Dowling et al., 2007). The gene discussed is MTOR; the disease is cancer.